BACKGROUND: Five-year disease-free survival rates for localised prostate cancer following standard doses of conventional radical external beam radiotherapy are around 80%. Conformal radiotherapy (CFRT) raises the possibility that radiotherapy doses can be increased and long-term efficacy outcomes improved, with safety an important consideration. METHODS: MRC RT01 is a randomised controlled trial of 862 men with localised prostate cancer comparing Standard CFRT (64Gy/32f) versus Escalated CFRT (74Gy/37f), both administered with neo-adjuvant androgen suppression. Early toxicity was measured using physician-reported instruments (RTOG, LENT/SOM, Royal Marsden Scales) and patient-reported questionnaires (MOS SF-36, UCLA Prostate Cancer Index, FACT-P). RESULTS: Overall early radiotherapy toxicity was similar, apart from increased bladder, bowel and sexual toxicity, in the Escalated Group during a short immediate post-radiotherapy period. Toxicity in both groups had abated by week 12. Using RTOG Acute Toxicity scores, cumulative Grade 2 bladder and bowel toxicity was 38% and 30% for Standard Group and 39% and 33% in Escalated Group, respectively. Urinary frequency (Royal Marsden Scale) improved in both groups from pre-androgen suppression to 6 months post-radiotherapy (p<0.001), but bowel and sexual functioning deteriorated. This pattern was supported by patient-completed assessments. Six months after starting radiotherapy the incidence of RTOG Grade > or = 2 side-effects was low (<1%); but there were six reports of rectal ulceration (6 Escalated Group), six haematuria (5 Escalated Group) and eight urethral stricture (6 Escalated Group). CONCLUSIONS: The two CFRT schedules with neo-adjuvant androgen suppression have broadly similar early toxicity profiles except for the immediate post-RT period. At 6 months and compared to before hormone therapy, bladder symptoms improved, whereas bowel and sexual symptoms worsened. These assessments of early treatment safety will be complemented by further follow-up to document late side-effects and efficacy.
BACKGROUND: Five-year disease-free survival rates for localised prostate cancer following standard doses of conventional radical external beam radiotherapy are around 80%. Conformal radiotherapy (CFRT) raises the possibility that radiotherapy doses can be increased and long-term efficacy outcomes improved, with safety an important consideration. METHODS: MRC RT01 is a randomised controlled trial of 862 men with localised prostate cancer comparing Standard CFRT (64Gy/32f) versus Escalated CFRT (74Gy/37f), both administered with neo-adjuvant androgen suppression. Early toxicity was measured using physician-reported instruments (RTOG, LENT/SOM, Royal Marsden Scales) and patient-reported questionnaires (MOS SF-36, UCLA Prostate Cancer Index, FACT-P). RESULTS: Overall early radiotherapy toxicity was similar, apart from increased bladder, bowel and sexual toxicity, in the Escalated Group during a short immediate post-radiotherapy period. Toxicity in both groups had abated by week 12. Using RTOG Acute Toxicity scores, cumulative Grade 2 bladder and bowel toxicity was 38% and 30% for Standard Group and 39% and 33% in Escalated Group, respectively. Urinary frequency (Royal Marsden Scale) improved in both groups from pre-androgen suppression to 6 months post-radiotherapy (p<0.001), but bowel and sexual functioning deteriorated. This pattern was supported by patient-completed assessments. Six months after starting radiotherapy the incidence of RTOG Grade > or = 2 side-effects was low (<1%); but there were six reports of rectal ulceration (6 Escalated Group), six haematuria (5 Escalated Group) and eight urethral stricture (6 Escalated Group). CONCLUSIONS: The two CFRT schedules with neo-adjuvant androgen suppression have broadly similar early toxicity profiles except for the immediate post-RT period. At 6 months and compared to before hormone therapy, bladder symptoms improved, whereas bowel and sexual symptoms worsened. These assessments of early treatment safety will be complemented by further follow-up to document late side-effects and efficacy.
Authors: Bradley A Erickson; Jack W McAninch; Michael L Eisenberg; Samuel L Washington; Benjamin N Breyer Journal: J Urol Date: 2010-11-13 Impact factor: 7.450
Authors: James M Wilson; David P Dearnaley; Isabel Syndikus; Vincent Khoo; Alison Birtle; David Bloomfield; Ananya Choudhury; John Graham; Catherine Ferguson; Zafar Malik; Julian Money-Kyrle; Joe M O'Sullivan; Miguel Panades; Chris Parker; Yvonne Rimmer; Christopher Scrase; John Staffurth; Andrew Stockdale; Clare Cruickshank; Clare Griffin; Emma Hall Journal: Int J Radiat Oncol Biol Phys Date: 2018-01-09 Impact factor: 7.038
Authors: Douglas H Brand; Sarah C Brüningk; Anna Wilkins; Katie Fernandez; Olivia Naismith; Annie Gao; Isabel Syndikus; David P Dearnaley; Alison C Tree; Nicholas van As; Emma Hall; Sarah Gulliford Journal: Int J Radiat Oncol Biol Phys Date: 2021-01-04 Impact factor: 7.038
Authors: Isabel Syndikus; Rachel C Morgan; Matthew R Sydes; John D Graham; David P Dearnaley Journal: Int J Radiat Oncol Biol Phys Date: 2009-10-14 Impact factor: 7.038
Authors: S Stanley; S Griffiths; M R Sydes; A R Moore; I Syndikus; D P Dearnaley Journal: Clin Oncol (R Coll Radiol) Date: 2008-06-18 Impact factor: 4.126
Authors: Tengbin Xiong; Rebecca M Turner; Yinghui Wei; David E Neal; Georgios Lyratzopoulos; Julian P T Higgins Journal: BMJ Open Date: 2014-05-15 Impact factor: 2.692